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http://dx.doi.org/10.1016/j.jmii.2013Background: Urinary tract infection (UTI) caused by resistant bacteria is becoming more prev-
alent. Few studies are available regarding community-onset UTIs caused by extended-
spectrum b-lactamase (ESBL)-producing bacteria in children.
Materials and methods: During a 5-year period, hospitalized children with community-onset
UTI caused by ESBL-producing Escherichia coli (case) and those with non-ESBL-producing
E. coli (control) were identified. Patients with long-term care facility stay within the preceding
month and those with urine cultures obtained >72 hours after admission were excluded. Clin-
ical features and risk factors associated with the occurrence of ESBL-producing E. coli UTI were
reviewed.
Results: The prevalence of UTI due to ESBL-producing E. coli increased slightly from 0.59% in
2002 to 0.96% in 2006. A total of 104 cases and 208 controls were included for comparison. The
ciprofloxacin resistance of the ESBL-producing E. coli increased significantly in this period
(p Z 0.006). Pre-existing neurological diseases (p < 0.001), use of antibiotics in the pastof Pediatrics, Chang Gung Memorial Hospital, 222 Mai-Chn Road, Keelung, Taiwan.
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400 N.-C. Fan et al.3 months (p < 0.001), and recent hospitalization within 1 month (p < 0.001) were found to be
potential risk factors. Moreover, previous exposure to third-generation cephalosporins
(p < 0.001) and aminoglycosides (p < 0.001) was associated with the selection of ESBL-
producing E. coli. Children with ESBL-producing E. coli UTIs had a longer hospital stay
(p Z 0.031) than those without.
Conclusions: ESBL-producing E. coli gradually became coresistant to other broad-spectrum an-
tibiotics, notably ciprofloxacin. UTIs caused by such resistant organisms led to a longer hospital
stay and more antibiotic use. Reinforcement of infection control measures, especially hand
washing in childcare settings and antibiotic stewardship, is critical to reduce the spread of
ESBL-producing E. coli.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Extended-spectrum b-lactamases (ESBLs) are enzymes that
mediate resistance to the newer b-lactam antibiotics,
including extended-spectrum cephalosporins and mono-
bactams.1e3 ESBL-producing organisms were first reported
in the early 1980s, shortly after the introduction of the
oxyimino b-lactam agents, and have now become wide-
spread all over the world.4 These enzymes are produced by
the members of the Enterobacteriaceae family, mainly
Escherichia coli, Klebsiella pneumoniae, and Klebsiella
oxytoca, which are the primary infectious agents that cause
urinary tract infection (UTI) in children.5
Isolation of ESBL-producing organisms typically occurred
in hospital settings and other healthcare facilities; howev-
er, such organisms have begun to disseminate in the com-
munity, and the incidence of community-onset UTIs due to
ESBL-producing strains has increased worldwide.6e10
Furthermore, the ESBL-producing strains are becoming
increasingly resistant to other non-b-lactam antimicrobials,
which poses significant therapeutic challenges.7
In order to understand the changing epidemiology and
solve the therapeutic difficulties, several studies have been
conducted to analyze the risk factors of infections associated
with ESBL-producing strains in adults.11,12 However, limited
data are available regarding community-onset infections
caused by ESBL-producing strains in children. The aim of this
study was to determine the risk factors of community-onset
UTIs caused by ESBL-producing E. coli in children.Materials and methods
Study design and participants
A 5-year, retrospective, caseecontrol study was designed
to characterize the clinical manifestations, laboratory
findings, antimicrobial susceptibilities, and risk factors of
UTI due to ESBL-producing E. coli in children. The case
group consisted of patients with culture-confirmed UTI due
to ESBL-producing E. coli and the controls were those with
UTI due to non-ESBL-producing E. coli. Cases and controls
were matched by age and sex in a 1:2 ratio.
Hospitalized patients aged <15 years with any urine
culture positive for E. coli were identified from the recordsof the Clinical Microbiology Laboratory of Chang Gung
Children’s Hospital during a 5-year period. Patients with UTI
due to E. coli were selected for this study. Long-term care
facility stay within the preceding month and isolates
recovered more than 72 hours after hospitalization were
the criteria of exclusion. The definitions of UTI were
dependent on different urine collection methods.13 If
midstream urine or a urine bag was used for collection of
midstream urine, UTI was defined by a positive urine cul-
ture (105 cfu/mL) or a positive urine culture (104e105 cfu/
mL) with pyuria (10 leukocytes per high-power field). If
catheterization was used for urine collection, UTI was
defined by a positive urine culture (103 cfu/mL).
All decisions regarding the antibiotic therapy were made
by the attending physicians who took care of the patients.
The initial antibiotic regimen was administered after blood
and urine samples had been taken for culture. The defini-
tive antimicrobial therapy was given after the culture re-
sults were obtained. The antibiotic regimen was considered
appropriate if it contained at least one drug that was active
in vitro against the subsequent E. coli isolate. An inappro-
priate initial antimicrobial therapy comprised the use of a
regimen without any appropriate drug to which the causa-
tive organism was sensitive. Early treatment failure or
worsening clinical conditions meant that fever persisted for
more than 3 days despite treating with antibiotics, and
antibiotics would be changed within 3e5 days to improve
the above clinical conditions.
ESBL determination was performed phenotypically with
ceftazidime/ceftazidime clavulanate and cefotaxime/
cefotaxime clavulanate disks, as recommended by the
Clinical and Laboratory Standards Institute (CLSI).14 Anti-
microbial susceptibility testing was performed using the
disk diffusion method, according to the CLSI standards.14Statistical analysis
Data were analyzed using SPSS, version 12.0 (SPSS Inc.,
Chicago, IL, USA). Student t test was used to analyze nu-
merical data. If the data were not normally distributed, the
ManneWhitney U test was used to compare nonparametric
data. A chi-square test or Fisher’s exact test was used to
analyze categorical data. A p value of <0.05 was consid-
ered statistically significant.
Figure 1. Longitudinal trends of antimicrobial resistance
among ESBL-producing Escherichia coli isolates collected from
urine cultures, 2002e2006. ESBL Z extended-spectrum b-lac-
tamase; NS Z not significant; TMP-SMX Z trimethoprime
sulfamethoxazole.
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Antimicrobial susceptibility of ESBL-producing
E. coli causing UTI
During the study period, a total of 6467 culture samples
were positive for E. coli, according to the records of the
Clinical Microbiology Laboratory of Chang Gung Children’s
Hospital. In all, 312 patients with UTI due to E. coli were
included in this study.Table 1 Characteristics of UTI caused by ESBL-producing Esche
Variables ESBL-p
E. coli
Underlying diseases
Percentage of underlying disease 1.87
Neurological disease 22 (21
Epilepsy 12 (11
Cerebral palsy 22 (21
Failure to thrive 12 (11
Developmental delay 14 (13
Hemato-oncologic disease 7 (6.
Nephrologic disease 20 (19
Vesicoureteral reflux 6 (5.
Neurogenic bladder 12 (11
Endocrine and genetic disease 7 (6.
Implanted device 19 (18
Foley 7 (6.
Nasogastric tube 12 (11
Previous medical conditions
Recurrent urinary tract infection 29 (27
Frequent urinary tract infection (>3 times/y) 14 (13
Use of antibiotics within previous 3 mo 49 (47
Use of immunosuppressive agents within 1 mo 2 (1.
Recent operation within 1 mo 6 (5.
Recent hospitalization within 1 mo 52 (50
Length of stay (d) 18.2
ICU care within previous 1 mo 14 (13
Data are presented as n (%) unless otherwise indicated. ESBL Z
UTI Z urinary tract infection.ESBL production was detected in 104 of the 312 (33.3%)
E. coli isolates obtained from urine cultures. Each of the
312 E. coli strains was isolated from an individual patient.
The proportions of ESBL-producing E. coli causing UTI were
0.59% in 2002, 0.81% in 2003, 0.85% in 2004, 0.90% in 2005,
and 0.96% in 2006. Fig. 1 shows the longitudinal trends of
resistance to different kinds of antimicrobial agents among
the ESBL-producing E. coli obtained from urine cultures. Of
these isolates, the antimicrobial resistance rate to amino-
glycosides such as gentamicin or amikacin (p < 0.001)
showed a decrease during the study period; however, rates
of resistance to ciprofloxacin (p Z 0.006) and flomoxef
have been increasing over the years.Risk factors for the occurrence of ESBL-producing
E. coli causing UTI
One hundred and four children with UTI due to ESBL-
producing E. coli and 208 matched controls with UTI due
to non-ESBL-producing E. coli were included in the study.
Three main risk factors evaluated included underlying dis-
eases, pre-existing medical conditions, and the use of an-
tibiotics in the past 3 months. The underlying diseases were
similar between the case patients and the controls, except
that there were more cases with neurological diseases
(21.2% vs. 5.3%, p < 0.001), failure to thrive (11.5% vs.
4.8%, p Z 0.032), developmental delay (13.5% vs. 3.8%,
p Z 0.032), and implanted device (18.3% vs. 14.9%,
p < 0.001) than the controls (Table 1). Furthermore,richia coli
ositive
(n Z 104)
ESBL-negative
E. coli (n Z 208)
p
0.75 <0.001
.2) 11 (5.3) <0.001
.5) 4 (1.9) 0.005
.2) 2 (1.0) 0.012
.5) 10 (4.8) 0.032
.5) 8 (3.8) 0.032
7) 2 (1.0) 0.797
.2) 31 (14.9) 0.228
8) 12 (5.8) 0.548
.5) 6 (2.9) 0.058
7) 31 (14.9) 0.193
.3) 31 (14.9) <0.001
7) 5 (2.4) 0.118
.5) 4 (1.9) <0.001
.9) 42 (20.2) 0.018
.5) 15 (7.2) 0.113
.1) 37 (17.8) <0.001
9) 1 (0.5) 0.538
8) 6 (2.9) 0.349
.0) 39 (18.8) <0.001
5.9 0.003
.5) 4 (1.9) <0.001
extended-spectrum b-lactamase; ICU Z intensive care unit;
Table 2 Comparison of antimicrobial agents used in the past 3 months between children with UTIs due to ESBL-producing and
non-ESBL-producing Escherichia coli
Antibiotics class ESBL-positive
E. coli (n Z 104)
ESBL-negative
E. coli (n Z 208)
p
Any antibiotics 49 (47.1) 37 (17.8) <0.001
First-generation cephalosporins 17 (16.3) 16 (7.7) 0.032
Second-generation cephalosporins 7 (6.7) 10 (4.8) 0.659
Third-generation cephalosporins 10 (9.6) 2 (1.0) <0.001
Ceftazidime 6 (5.8) 0 (0.0) 0.002
Cefotaxime 5 (4.8) 0 (0.0) 0.007
Ceftriaxone 3 (2.9) 2 (1.0) 0.425
Fourth-generation cephalosporins 1 (1.0) 2 (1.0) 0.538
Penicillin-based antibiotics 30 (28.8) 23 (11.1) <0.001
Ampicillin 24 (23.1) 13 (6.3) <0.001
Amoxicillin 6 (5.8) 10 (4.8) 0.928
Quinolones 1 (1.0) 2 (1.0) 0.538
Trimethoprimesulfamethoxazole 3 (2.9) 6 (2.9) 0.720
Aminoglycoside 30 (28.8) 14 (6.7) <0.001
Vancomycin 9 (8.7) 2 (1.0) 0.002
Macrolide 3 (2.9) 4 (1.9) 0.252
Carbapenem 2 (1.9) 0 (0.0) 0.201
Data are presented as n (%) unless otherwise indicated. ESBL Z extended-spectrum b-lactamase; UTI Z urinary tract infection.
402 N.-C. Fan et al.recurrent UTI (27.9% vs. 20.2%, p Z 0.018), use of antibi-
otics in the past 3 months (47.1% vs. 17.8%, p < 0.001),
recent hospitalization within 1 month (50% vs. 18.8%,
p < 0.001), and care in intensive care units in the past 1
month (13.5% vs. 1.9%, p < 0.001) were more frequently
found in the case patients than in the controls (Table 1).
Table 2 shows a comparison of the antimicrobial agents
used in the past 3 months. The use of first-generation
(16.3% vs. 7.7%, p Z 0.032) or third-generation (9.6% vs.
1.0%, p < 0.001) cephalosporins, aminoglycosides (28.8% vs.
6.7%, p < 0.001), and vancomycin (8.7% vs. 1.0%, p < 0.002)Table 3 Analysis of clinical features of UTI due to ESBL-produc
Variables ESBL-positi
E. coli (n Z
Symptoms and signs
Fever (>38.3C) 72 (69.2)
Febrile duration prior to admission (d) 5.16
Dysuria 12 (11.5)
Frequency/urgency 5 (4.8)
Abdominal pain 7 (6.7)
Flank pain 0 (0.0)
Laboratory findings
WBC count (/mL) 12,517.1
Hemoglobin (g/dL) 10.9
Platelet (/mL) 348,381.7
Segment (%) 48.9
Band (%) 2.3
CRP (mg/L) 53.9
BUN (mg/dL) 15.4
Creatinine (mg/dL) 0.4
Data are presented as n (%) unless otherwise indicated. BUN Z blo
spectrum b-lactamase; UTI Z urinary tract infection; WBC Z whitewas found significantly more frequently in patients with UTI
due to ESBL-producing E. coli.Clinical manifestations and outcomes
An analysis of the clinical features of UTI due to ESBL-
producing E. coli is shown in Table 3. Longer febrile dura-
tion prior to admission (5.16 vs. 2.76 days, p < 0.001) and
abdominal pain (6.7% vs. 4.3%, p Z 0.032) were more
frequently found in the case group. There was no significanting Escherichia coli
ve
104)
ESBL-negative
E. coli (n Z 208)
p
161 (77.4) 0.154
2.76 <0.001
28 (13.5) 0.528
10 (4.8) 0.779
9 (4.3) 0.032
9 (4.3) 0.073
13,304.4 0.716
11.3 0.316
342,271.4 0.446
52.7 0.283
3.0 0.121
66.5 0.351
14.4 0.853
0.6 0.188
od urea nitrogen; CRP Z C-reactive protein; ESBL Z extended-
blood cell.
Table 4 Univariate logistic regression analyses of the hospitalization history associated with the occurrence of UTI due to
ESBL-producing Escherichia coli
Variables ESBL-positive
E. coli (n Z 104)
ESBL-negative
E. coli (n Z 208)
p
Clinical characteristics
Total duration of fever (d) 3.9 3.6 0.679
Total duration of local urologic symptomsa (d) 1.97 2.37 0.606
Total duration of admission (d) 12.08 6.88 0.031
ICU hospitalization 26 (25.0) 38 (18.2) 0.215
Duration of ICU hospitalization 27.4 15.1 0.129
Positive findings in renal ultrasoundb 52 (75.4) 122 (81.3) 0.403
Antibiotic exposure
Total duration of antibiotics therapy (d) 9.7 8.9 0.388
Duration of fever after antibiotic treatment (d) 1.9 1.7 0.624
Duration of initial antibiotics usage (d) 4.6 4.8 0.712
Inappropriate initial antibioticsc 64 (61.5) 9 (4.3) <0.001
Early treatment failured 19 (18.3) 14 (6.7) 0.003
Clinical outcomes
Improvement without antibiotics 11 (10.6) 14 (6.7) 0.338
Improvement without modification of initial antibiotics 31 (29.8) 73 (35.1) 0.420
Improvement with modification of initial antibiotics 59 (56.7) 119 (54.8) 0.840
Initial antibiotic regimen inactive in vitro against the isolate
from the initial urine culture
31 (52.5) 30 (26.3) 0.001
Due to worsening clinical conditionsd 24 (40.7) 22 (10.6) 0.004
Due to improvement of initial clinical conditionse 16 (27.1) 80 (38.5) <0.001
Recurrent UTI 35 (33.6) 49 (23.6) 0.078
a Local urological symptoms include dysuria, urinary frequency/urgency, and flank pain.
b Positive findings of renal ultrasound include renal pelviectasis, hydronephrosis, and bladder mucosa thickening.
c Inappropriate initial antibiotics mean that all antibiotics were inactive in vitro against isolates from the initial urine cultures.
d Early treatment failure or worsening clinical conditions mean that fever persisted for more than 3 days after antimicrobial therapy
despite continuation of antibiotic treatment. Antibiotic regimen was usually modified in 3e5 days due to the worsening clinical
conditions.
e The use of antibiotics was de-escalated because of the improvement of initial clinical conditions.
Data are presented as n (%) unless otherwise indicated. ESBL Z extended-spectrum b-lactamase; ICU Z intensive care unit;
UTI Z urinary tract infection.
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tients and the controls.
Table 4 reveals the univariate logistic regression ana-
lyses of the hospitalization history associated with UTI due
to ESBL-producing E. coli. We found that children in the
case group had longer durations of hospitalization (12.08
vs. 6.88 days, p Z 0.031). Furthermore, early treatment
failure, defined as fever persisting for more than 3 days
despite antibiotic therapy, was more common in the case
patients than in the controls (18.3% vs. 6.7%, p Z 0.003).
For their worsening clinical conditions, the case patients
required antibiotic adjustment more frequently than the
controls, according to the obtained urine culture results
(40.7% vs. 10.6%, pZ 0.004); however, the controls usually
were overtreated with antibiotics initially and needed a de-
escalation after the culture results were available (27.1%
vs. 38.5%, p < 0.001).Discussion
The purpose of this study is to highlight the emergence of
community-acquired ESBL-producing E. coli in children, andthis emergence limits therapeutic choices and increases
morbidity of pediatric UTI. More importantly, we report the
clinical risk factors and characteristics of pediatric patients
who acquired ESBL-producing E. coli from UTI.
A major concern regarding ESBL-producing E. coli is its
high rate of coresistance to non-b-lactam antibiotics,
particularly quinolones, trimethoprimesulfamethoxazole,
and aminoglycosides.15 In this study, antimicrobial resis-
tance to aminoglycosides was found to decrease; however,
rates of resistance to ciprofloxacin and flomoxef have been
increasing. These findings suggest that a change might have
occurred in the clonal composition or the plasmid structure
of the strains during the study period. High ciprofloxacin
resistance among ESBL-producing E. coli was also found in
other countries. Studies from Israel in 2004 and Spain in
2006 reported that ciprofloxacin resistance was 39% and
31.5% in ESBL-producing E. coli isolates, respectively.6,8 In
Turkey, an extremely high rate of ciprofloxacin resistance
(84%) among ESBL-producing E. coli was reported.15 Flo-
moxef, a cephamycin that is unique in its structure by
containing a difluoromethylthioacetamido group at position
7, has better in vitro activity against ESBL-producing
Enterobacteriaceae.16 Consistent with the increasing
404 N.-C. Fan et al.resistance of ESBL-producing Enterobacteriaceae to flo-
moxef observed in our study, an increase in bloodstream
infections caused by flomoxef-resistant ESBL-producing K.
pneumoniae was also reported from Taiwan in 2004.16
Subsequent studies found that the in vivo acquisition of
the plasmid-mediated AmpC b-lactamase gene (blaDHA-1)
leading to flomoxef nonsusceptibility has occurred in ESBL-
producing Enterobacteriaceae following a prolonged expo-
sure to flomoxef.17 This multidrug resistance nature of
ESBL-producing bacteria would cause problems in the
treatment of infections caused by such organisms.
Regarding risk factors associated with the occurrence of
UTI due to ESBL-producing E. coli, underlying diseases such
as neurological diseases, failure to thrive, and develop-
mental delay were found to be associated with such
infection in children. The result was different from previous
studies in that urinary abnormalities or previous urological
operations, which were less frequently found in our series,
were found to be potential risk factors associated with UTIs
caused by ESBL-producing E. coli.18,19 This discrepancy may
be because these studies involved different patient pop-
ulations (adults) and, in general, urological operations are
less common in children than in adults. Nevertheless,
recurrent UTI and recent hospitalization, two risk factors
identified in our study, were also found to be associated
with ESBL-producing E. coli infection in other reports.9,15
These results suggest that children may acquire ESBL-
producing E. coli during healthcare processes and become
a reservoir for ESBL producers, which may subsequently
result in the occurrence of UTI when they return to the
community.
In terms of antibiotic use, our study showed that the
previous use of aminoglycosides, first- and third-generation
cephalosporins, and vancomycin was associated with UTIs
caused by ESBL-producing E. coli. Similar findings have
been reported by Topaloglu et al,1 who found that exposure
to second- and third-generation cephalosporins and other
antibiotics (aminoglycosides, quinolones, and carbape-
nems) was a potential risk factor for the occurrence of
ESBL-producing E. coli UTIs in children. By contrast, the
results of other studies in adults with ESBL-producing bac-
teria were diverse. Previous use of cefuroxime, second- and
third-generation cephalosporins, or quinolones was found
to be associated with ESBL-producing bacteria.6,8,18 These
results suggest that third-generation cephalosporins or
quinolones may select for ESBL-producing E. coli from the
existing gastrointestinal flora when a patient is exposed to
this agent. One study from Spain indicated that the prev-
alence of fecal ESBL-producing E. coli has increased in the
past decade, and in fact, up to 5.5% of fecal E. coli present
in feces of healthy volunteers was found to produce
ESBLs.20
Comparing the clinical manifestations, longer febrile
duration prior to admission, prolonged hospital stay, and
early treatment failure were frequently found in ESBL-
producing E. coli UTIs in children. The result implies that an
unfavorable outcome may occur if ESBL-producing E. coli is
present; however, in our series, there was no attributable
mortality.
Our data showed an increasing trend in the occurrence
of community-onset UTI caused by ESBL-producing E. coli.
Although these infections are currently not very common inchildren, it is possible that clinicians will more frequently
be confronted with such infections occurring in the com-
munity in the near future, a scenario similar to that of
community-associated methicillin-resistant Staphylococcus
aureus in pediatric patients.3 Thus, to minimize the spread
of ESBL-producing E. coli, aggressive infection control
measures should be emphasized in both hospital and com-
munity settings. Most patients with ESBL-producing E. coli
infections have previously been colonized by such organ-
isms in the gastrointestinal tract.20 Hand washing therefore
is critical to prevent the spread of bacteria and occurrence
of infection. Besides, judicious use of antibiotics is impor-
tant. Kim et al21 reported that restriction on the use of
third-generation cephalosporins through a computer-
assisted system can control the spread of ESBL-producing
bacteria in hospital settings.
In conclusion, the incidence of community-onset UTIs
caused by ESBL-producing E. coli in children seems to be
increasing, and this emerging issue complicates the use of
antibiotics in the management of UTI in children. Adequate
infection control, rapid detection of the resistant bacteria,
and antibiotic stewardship are important in terms of halting
the spread of ESBL-producing bacteria. Further clinical in-
vestigations are needed to guide clinicians in the treatment
of community-onset UTIs caused by ESBL producers in
children.
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